This Stock Should Be the Fastest-Growing Pot Stock in 2020

Auxly Cannabis (TSX:XLY) is well-positioned to deliver tremendous growth in 2020.

Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The cannabis sector as a whole had a rough time in 2019. The Horizons Marijuana Life Sciences ETF, which copies the performance of the North American Marijuana Index, has fallen more than 30% year to date. Cannabis stocks fell sharply as investors’ enthusiasm for strong growth prospects and mergers of successful companies faded.

Limits on the types of cannabis products companies can sell were lifted in October. Companies should start selling foods, beverages, and other marijuana-infused products this month. If there is a significant increase in sales, it could help push stock prices higher.

Industry analysts predict that the marijuana market will continue to grow over the next decade, which should bode well for cannabis stocks.

A small pot stock with tremendous growth

There are some small pot stocks worth considering to invest in. While most of them are not turning a profit yet, their revenue is increasing fast. One of them, Auxly Cannabis Group (TSX:XLY), is expected to have the fastest growth in revenue in 2020. Indeed, the pot producer should increase its revenue at a stunning rate of 1,108.90%, from $5.2 million to $62.5 million.

Let’s look at possible triggers for such a strong growth rate.

Major deals to increase Auxly’s revenue in 2020

This strong growth’s prediction can be explained by the fact that Auxly’s major agreements and partnerships won’t be coming into full effect until next year. For example, most of the company’s production will come from its joint venture with Sunens to build a 1.4 million square foot greenhouse in Ontario, and this won’t be licensed and operational until the second quarter of next year.

The second wave of cannabis legalization, which came into effect on October 18, allows the sale of edibles, topicals, and concentrates for recreational use. Auxly is really well positioned to benefit as it has actually suspended the production of dried cannabis flowers with the intention of using it for derivatives. As the derivatives market has a higher margin than dried marijuana flowers, it is a wise decision from management to maintain inventory for derivatives products.

In August, Auxly signed a cultivation and purchase agreement with hemp growers in Prince Edward Island. This deal will allow Auxly to receive all the hemp produced on a 300-acre farm. Cultivation began this fall and will position Auxly to thrive in the booming CBD market.

According to Auxly, this project will increase the company’s ability to meet the growing market demand for wellness and CBD-based products. It should also enhance its commitment to bring innovative, branded derivative cannabis products to Canadian consumers.

The biggest benefit for Auxly is expected to come from a US$123 million deal recently signed with British tobacco giant Imperial Brands. This partnership will allow the Vancouver pot company to have access to Imperial’s global licenses for its vaping technology. In return, Imperial will receive a 19.9% interest in Auxly shares at a price of $0.81 per share, which is significantly higher than the current value of Auxly.

This capital investment should help Auxly to achieve its ambitions for 2020, as it seeks to expand into the vaping market, which is expected to grow significantly in the Cannabis 2.0 market. It remains to be seen whether Auxly stock will really be the fastest-growing pot stock of 2020, but the company certainly seems well-positioned to do so.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Stephanie Bedard-Chateauneuf owns shares of Horizons Medical Marijuana Life Sci ETF. The Motley Fool recommends Auxly Cannabis Group.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »